Literature DB >> 11997305

Pneumocystis carinii.

Ann E Wakefield1.   

Abstract

Pneumocystis carinii is an atypical fungus that causes pneumonia in immunocompromised individuals. P. carinii comprises a heterogeneous group of organisms that have been isolated from a wide range of mammalian host species. P. carinii infection is host species specific, the P. carinii organisms that infect humans have only been found in humans. This review discusses the application of molecular techniques to the study of the biology and epidemiology of P. carinii infection. It addresses the use of DNA amplification for the detection and diagnosis of P. carinii pneumonia. Studies investigating the reservoir of infectious P. carinii organisms, the routes of transmission of the infection, and the emergence of drug resistant strains of P. carinii are also discussed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11997305     DOI： 10.1093/bmb/61.1.175

Source DB:  PubMed          Journal:  Br Med Bull        ISSN： 0007-1420            Impact factor:   4.291


  9 in total

1.  Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia.

Authors:  N Lubis; D Baylis; A Short; J Stebbing; A Teague; S Portsmouth; M Bower; M Nelson; B Gazzard
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

2.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

3.  PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immuno-compromised patients.

Authors:  Somchai Pinlaor; Piroon Mootsikapun; Porntip Pinlaor; Anakapong Phunmanee; Vichit Pipitgool; Paiboon Sithithaworn; Worawan Chumpia; Jiraporn Sithithaworn
Journal:  Parasitol Res       Date:  2004-09-01       Impact factor: 2.289

4.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

5.  The mycological and molecular study of Pneumocystis jiroveci pneumonia among HIV and non-HIV immunocompromised patients hospitalized in pulmonary units in Guilan, Northern Iran.

Authors:  Zahra Rafat; Keyhan Ashrafi; Seyed Jamal Hashemi; Elahe Sasani; Alireza Naserani; Hasti Kamali Sarvestani; Farshid Hashemi
Journal:  Iran J Microbiol       Date:  2021-08

6.  Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.

Authors:  Vivian Cody; Jim Pace; Andre Rosowsky
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-08-13

7.  Pregnancy and asymptomatic carriage of Pneumocystis jiroveci.

Authors:  Sergio L Vargas; Carolina Angelica Ponce; Catherine Andrea Sanchez; Ana Victoria Ulloa; Rebeca Bustamante; Guido Juarez
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

8.  Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Authors:  Kieran R Daly; Judy Koch; Linda Levin; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

9.  Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor.

Authors:  Chad Steele; Luis Marrero; Steve Swain; Allen G Harmsen; Mingquan Zheng; Gordon D Brown; Siamon Gordon; Judd E Shellito; Jay K Kolls
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.